CN110526957A - Premeabilisation of cells enhances peptide, composition and its application - Google Patents
Premeabilisation of cells enhances peptide, composition and its application Download PDFInfo
- Publication number
- CN110526957A CN110526957A CN201910585047.1A CN201910585047A CN110526957A CN 110526957 A CN110526957 A CN 110526957A CN 201910585047 A CN201910585047 A CN 201910585047A CN 110526957 A CN110526957 A CN 110526957A
- Authority
- CN
- China
- Prior art keywords
- cpep
- premeabilisation
- peptide
- cells
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to Premeabilisation of cells to enhance peptide, the composition comprising Premeabilisation of cells enhancing peptide and combinations thereof, polypeptide factor and optional ATP and their applications in cosmetics or skin care item.The invention further relates to the preparation methods of the composition.Premeabilisation of cells enhancing peptide of the invention and combinations thereof can effectively enhance the transdermal effect of polypeptide factor isoreactivity macromolecular, and then preferably play its beauty, skin-care effect.
Description
Technical field
The invention belongs to cosmetic technical fields, and in particular to Premeabilisation of cells enhances peptide, enhances comprising the Premeabilisation of cells
The composition of peptide and they preparing the application in cosmetics or skin care item.
Background technique
Transdermal delivery efficiencies ingredient is a kind of noticeable systemic drug delivery approach, have it is painless, reliable, be directed to
Property, it is efficient the features such as.However, due to using the barrier limitation by skin barrier, especially cuticula, so macromolecular is saturating
Skin delivering is still a challenge.In cosmetic field, the large biological molecules such as oligopeptides, polypeptide factor, competent cell extract are living
Property ingredient since significant effect is increasingly by the approval of industry, but these functional components are required to through skin barrier pair
Skin Cell carries out the effects of signal activation, therefore develops a kind of transdermal scheme for active macromolecules functional component, to increasing
Johnson & Johnson's object skin care item effect plays a significant role.
For example, Chinese patent application CN 106084006A discloses a kind of transdermal peptide and its application, and in particular to have sequence
The transdermal enhancing peptide of ACSSTKKHCG, and its application in cosmetic formulation, hair-cosmetic formulations or pharmaceutical composition are arranged, and claims and makes
With the transdermal enhancing peptide, the Transdermal absorption of active material can be realized in the case where not damaging skin.
For another example, Chinese patent application CN 108186392A discloses a kind of skin care beauty containing epithelical cell growth factor
Hold composition and its preparation method and application, and in particular to amino acid sequence ACSSTPSKHCG, ACSTSPSKHCG,
The transdermal peptide of ACSTTPSKHCG, ACSSRPSKHCG, ACSRSPSKHCG, ACSRRPSKHCG, with epithelical cell growth factor
And the composition of water can greatly enhance the transdermal ability of epidermal growth factor, so that epithelical cell growth factor is able to
Enter dermal layer of the skin through keratoderma, to play better beautification function.
As it can be seen that prior art kind has been proposed that active macromolecules function can be enhanced by what about 10-11 amino acid formed
The transdermal scheme of ingredient is imitated, however, inventor is had found by lot of experiments, when amino acid sequence changes, promotes big point
Larger change can also occur for the transdermal effect of son, lack foresight.Horn of plenty product category, it is still necessary to be directed to active macromolecules function
Imitate the new transdermal scheme of ingredient.
Summary of the invention
The object of the present invention is to provide the Premeabilisation of cells with completely new sequence to enhance peptide, and the combination comprising the enhancing peptide
Object can effectively promote the transdermal efficiency of cosmetic industry oligopeptides, the cell secretory polypeptide factor.
It is achieved through the following technical solutions above-mentioned purpose of the invention:
An aspect of of the present present invention provides Premeabilisation of cells enhancing peptide (cell penetration enhancement
Peptide is abbreviated as CPEP), the sequence with any one in amino acid sequence SEQ ID NO.1~SEQ ID NO.4.
Amino acid sequence SEQ ID NO.1~SEQ ID NO.4 specifically:
SEQ ID NO.1:CSSSSSKHC (CPEP-9)；
SEQ ID NO.2:CSSSSSKHCG (CPEP-10N)；
SEQ ID NO.3:ACSSSSSKHC (CPEP-10C)；With
SEQ ID NO.4:ACSSSSSKHCG (CPEP-11).
Another aspect provides composition, the composition includes:
Polypeptide factor, and
Any combination of any one or they in above-mentioned Premeabilisation of cells enhancing peptide.
By weight, the ratio between polypeptide factor and Premeabilisation of cells enhancing peptide are as follows: 5~10:1, preferably 8:1.
Preferably, the combination comprising four kinds of Premeabilisation of cells enhancing peptides in the composition, and by weight, each cell seeps
The ratio CPEP-9:CPEP-10N:CPEP-10C:CPEP-11 of enhancing peptide is 0.5~1.5:0.5~1.5:0.5~1.5:1 thoroughly
~3, preferably 1:1:1:2.
The polypeptide factor such as the people EGF factor, the people PDGF factor and the HGF factor or their any combination.
Preferably, contain ATP in the composition.
Preferably, the additional amount of ATP is 1~5 times of weight that the Premeabilisation of cells enhances peptide, for example, 1 times, 2 times, 3 times,
4 times, 5 times etc..
Another aspect of the invention provides the preparation method of the composition, and the method includes by polypeptide factor, thin
Born of the same parents permeate enhancing peptide and optional ATP is mixed.
Another aspect of the invention provide Premeabilisation of cells enhancing peptide and/or the composition prepare cosmetics or
Application in skin care item.
Further, according to the needs of preparation or application, the cosmetics or skin care item also include that other cosmetics can connect
The component received.
Inventor has successfully been obtained Premeabilisation of cells enhancing peptide recited above, passes through GeneScript biology by screening
Science and Technology Ltd. carries out synthesis in solid state, and carries out efficiency assay, as a result, it has been found that, four kinds of Premeabilisation of cells enhancing peptide can
Effectively facilitate the transdermal efficiency of cosmetic industry oligopeptides, the cell secretory polypeptide factor.Especially it has surprisingly been found that when will be upper
When stating four kinds of Premeabilisation of cells enhancing peptides and being applied in combination, the especially ratio of CPEP-9:CPEP-10N:CPEP-10C:CPEP-11 is
When 1:1:1:2, shows and permeate enhancing peptide more preferably scalp facilitation compared to single cell.In addition, inventor's also accident
It was found that ATP is added into composition, Premeabilisation of cells enhancing peptide and combinations thereof can be further enhanced to the transdermal rush of polypeptide factor
Into effect, and humidification depends on the concentration of ATP.
Brief Description Of Drawings
Fig. 1 is the structural schematic diagram of transdermal slot in Franz transdermal diffusion apparatus device used in embodiment 3.
Fig. 2 is that transdermal test samples after 2 hours in embodiment 3, with the column of slot total protein concentration under each group of BCA method measurement
Shape figure.
Fig. 3 is different time sampling in embodiment 3, with the histogram of slot total protein concentration under each group of BCA method measurement.
Fig. 4 is that transdermal test samples after 2 hours in embodiment 3, with the column of slot EGF concentration under each group of ELISA method measurement
Shape figure.
Fig. 5 is that transdermal test samples after 2 hours in embodiment 3, with the column of slot PDGF concentration under each group of ELISA method measurement
Shape figure.
Fig. 6 is that transdermal test samples after 2 hours in embodiment 3, with the column of slot HGF concentration under each group of ELISA method measurement
Shape figure.
Fig. 7 is when studying influence of the ATP to transdermal efficiency in embodiment 3, with the column for the lower slot HGF concentration that BCA method measures
Shape figure.
Specific embodiment
Unless otherwise indicated, all technical and scientific terms used herein all have such as those of ordinary skill in the art
The normally understood meaning of institute.In general, term as used herein is well known and is routinely used in this field.
Main terms used in the present invention are defined as follows:
As used herein, term " Premeabilisation of cells enhancing peptide " is to refer to that the transdermal of active macromolecules is promoted to pass
It send, to enhance the active peptide of active macromolecules effect, is usually made of 8 to 12 amino acid residues.It is currently preferred thin
Amino acid sequence such as SEQ ID NO.1~SEQ ID NO.4 that born of the same parents permeate enhancing peptide is illustrated.
As used herein, term " polypeptide factor " is properly termed as " polypeptide cytokines " again, refers to that one kind can be
Intercellular trafficking information, with immunoloregulation function, the peptide being made of 10~50 amino acid.Polypeptide factor passes through most of
Extracellular signal conduction adjusts a variety of biological functions, including congenital and acquired immunity, hematopoiesis, inflammation and reparation and proliferation.
Cell factor may act on their cell (Autocrine) of secretion, act on adjacent cells (paracrine action), or at certain
Distant place cell (endocrine effect) is acted in a little situations.In the present invention, the polypeptide factor is selected from the people EGF factor, people
Any combination of any one or they in the PDGF factor, the HGF factor.
In some embodiments, composition of the invention also includes ATP.When in the present compositions comprising ATP
When, the additional amount of ATP enhances 1 to 5 times of the weight of peptide, such as 1 times, 2 times, 3 times, 4 times or 5 times for the Premeabilisation of cells, with
And any number in above-mentioned content range.
In the preparation method of composition of the invention, it can use any hybrid technique process as known in the art will
Polypeptide factor, Premeabilisation of cells enhancing peptide are mixed with optional ATP, repeat no more specific hybrid technique process in this herein, this
Field technical staff can select appropriate hybrid technique according to actual needs.
In some embodiments, composition of the invention can be used for preparing cosmetics or skin care item.Make when herein
Used time, cosmetics refer to any position that human body surface is interspersed among with smearing, sprinkling or other similar method, such as skin, hair
Send out, refer to toenail, lips and teeth etc., to reach cleaning, maintenance, beauty, modification and change appearance, or amendment human scent, it keeps good
Chemistry and/or biological agent for the purpose of good state.Skin care item refer to protection skin, have the function of skin maintenance and cosmetic benefits, can enhance
The elasticity of skin and the chemistry and/or biological agent of vigor.As will be understood by the skilled person in the art, cosmetics and skin care item
And two concepts of non-critical differentiation, some chemistry and/or biological agent both can be used as cosmetics and can also be used as skin care item.
Therefore, as used herein, cosmetics and skin care item jointly include but is not limited to: toner, facial treatment milk, skin care
Frost, is felt well at face cleaning cream, mildy wash, face cleaning jelly, face cleaning foam, makeup remover, foundation cream, muffin, lipstick, eye cream, face cream, essence
Skin water, sun screen, BB frost etc..The unlimited setting state of cosmetics or skin care item preparation, such as, but not limited to creme, emulsion,
The form of gelling agent and facial mask etc..
Herein, cosmetics or skin care item preparation are in addition to including Premeabilisation of cells enhancing peptide of the invention and/or the present invention
Composition other than, also include the acceptable component of other cosmetics.
As used herein, described " the acceptable component of cosmetic ", which refers to, to be suitable for the mankind and compared with lower animal
Skin or hair contact without the known of unsuitable toxicity, incompatibility, unstability, irritation, allergic reaction etc.
Component.The acceptable component of cosmetic is such as, but not limited to water, alcohols, finish, surfactant, pH adjusting agent, antioxygen
Agent or preservative etc..
The application is described in detail below with reference to embodiment, but the application is not limited to these embodiments.
Unless otherwise instructed, the reagent being administered in embodiments herein is bought by commercial sources.
Embodiment
Embodiment 1: the detection (BCA method) of polypeptide factor total protein content
1. the drafting of standard curve: taking one piece of ELISA Plate, waiting to specifications is more bent for following standards than reagent dilutions
The drafting of line；
2. adding 1 volume BCA reagent B (50:1) to prepare appropriate BCA according to sample size by 50 volume BCA reagent As and working
Liquid mixes well；
3. 200 μ L BCA working solutions are added in each hole；
4. an ELISA Plate is put vibrates 30sec on the oscillator, 37 DEG C are placed 30 minutes, the then colorimetric estimation at 562nm.
With protein content (μ g) for abscissa, light absorption value is ordinate, draws standard curve；
5. diluting sample to be tested to suitable concentration, make 20 μ L of sample diluting liquid total volume, addition 200 μ L of BCA working solution,
It mixes well, after 37 DEG C are placed 30 minutes, reference is done with standard curve blank tube, the colorimetric under 562nm wavelength records extinction
Value；
6. corresponding protein content can be checked on standard curve according to the light absorption value of institute's sample, it is dilute divided by sample
Liquid total volume is released, is sample actual concentrations multiplied by sample extension rate.
Embodiment 2: the ELISA of transdermal front and back polypeptide factor key cytokines detects (ELISA method)
Wuhan doctor De Sheng is used respectively for the relative concentration detection of the people EGF factor, the people PDGF factor and the HGF factor
People EGF ELISA Kit (EK0325), the people PDGF-AB ELISA Kit (EK0484) and people HGF ELISA Kit of object
(EK0369).Step is summarized as follows:
1. collecting mescenchymal stem cell culture culture solution (i.e. polypeptide factor) two days later and empty culture solution control, centrifugation
Remove cell fragment.Every group of 6 technologies are parallel.
2. 100 μ l samples and empty map are added in every hole, 37 DEG C are reacted 90 minutes, are not washed.
3. 100 μ l biotin labelled antibodies are added in every hole, 37 DEG C are reacted 60 minutes.
4.0.01M TBS is washed 3 times.
5. every 100 μ lABC of hole addition, 37 DEG C are reacted 30 minutes.
6.0.01M TBS is washed 5 times.
7.TMB is protected from light within 30 minutes in 37 DEG C.
8. TMB terminate liquid is added, reading, and compare data between respective sets.
The test of embodiment 3:Franz transdermal diffusion apparatus device
Experimental group:
Comparative group: 5 μ g/mL 11AA ramdon oligo (amino acid sequence ACSSSPSKHC), 40 μ g/mL polypeptides because
Son；
CPEP-9 group: 5 μ g/mL CPEP-9,40 μ g/mL polypeptide factors；
CPEP-10N group: 5 μ g/mL CPEP-10N, 40 μ g/mL polypeptide factors；
CPEP-10C group: 5 μ g/mL CPEP-10C, 40 μ g/mL polypeptide factors；
CPEP-11 group: 5 μ g/mL CPEP-11,40 μ g/mL polypeptide factors；
CPEP group is combined: 5 μ g/mL CPEP combine (weight ratio=1:1:1:2 of CPEP-9/10N/10C/11), 40 μ g/
ML polypeptide factor.
Test method: intact unbroken SD rat (being purchased from Beijing only tonneau China Experimental Animal Center) skin of abdomen group is taken
It knits, unhairing is placed in physiological saline (0.9%NaCl aqueous solution) for use.By slot (receptor under transdermal slot (as shown in Figure 1)
Chamber it fills physiological saline 5ml in) and is put into a magnetic stir bar (stir bar), transdermal upper slot (donor
Chamber ready intact rat abdomen skin histology before) is coverd between lower slot, is separately added into it in upper slot
Before transdermal test polypeptide factor, synthetic Premeabilisation of cells enhancing peptide and combinations thereof, ATP etc. for preparing.Transdermal slot is placed in
In Franz transdermal diffusion apparatus, 37 DEG C of constant temperature, magnetic agitation rotating speed 300rpm, respectively in starting 5 minutes of transdermal diffusion apparatus, 4 small
When and 8 hours, take 200 μ l collection liquids from channel opening under transdermal slot, and after 5 minutes, sampling in 4 hours respectively under transdermal slot
200 μ l physiological saline are added at channel opening maintains collection liquid total volume in lower slot constant.By various time points from slot under transdermal slot
The collection liquid of middle taking-up carries out quantitative detection as measuring samples, using ELISA method and BCA method.
Test 1: it is combined using comparative group, CPEP-9 group, CPEP-10N group, CPEP-10C group, CPEP11 group and CPEP group
Transdermal test is carried out, test is sampled after 2 hours and detected through BCA method, as a result shown in table 1 and Fig. 2.
Table 1
| Group | Lower slot total protein concentration (ng/mL) |
| PBS | 210 |
| 11AA ramdon oligo | 430 |
| CPEP-9 | 2130 |
| CPEP-10N | 3210 |
| CPEP-10C | 3810 |
| CPEP-11 | 4580 |
| CPEP combination | 6950 |
As can be seen that CPEP and combination have significant facilitation, CPEP-11 to the skin permeation rate of polypeptide factor ingredient
Successively it is better than CPEP-10C, CPEP-10N, CPEP-9, and CPEP combination (CPEP-9/10N/10C/11) effect is optimal.
Test 2: selecting transdermal facilitation effect preferably CPEP-11 group and CPEP group to be combined, and carries out action time to transdermal
The influence of effect is studied, and each group is detected in test sampling in 10 minutes, 2 hours and 8 hours through BCA method respectively, is as a result shown in 2 He of table
In Fig. 3.
Table 2
The results show that CPEP and combinations thereof enhances the extension at any time of the transdermal humidification of polypeptide factor.
Test 3: it is combined using comparative group, CPEP-9 group, CPEP-10N group, CPEP-10C group, CPEP11 group and CPEP group
Carry out transdermal test, after test 2 hours sampling through ELISA method in polypeptide factor main component (including EGF, PDGF and
HGF it) is detected, is as a result shown in table 3 and Fig. 4-6.
Table 3
As can be seen that CPEP of the invention and combinations thereof has significant promote to the skin permeation rate of EGF, PDGF and HGF
Effect, CPEP-11 is better than CPEP-10C, CPEP-10N, CPEP-9, and CPEP combination (CPEP-9/10N/10C/11) effect is most
It is excellent.
Test 4: selecting transdermal facilitation effect preferably CPEP-11 group and CPEP group to be combined, and carries out ATP to transdermal effect
Research is influenced, each group sampling after test 2 hours is detected through BCA method, is as a result shown in table 4 and Fig. 7.
Table 4
The results show that under the action of ATP energy donor, the enhancing of CPEP and combination to polypeptide factor ingredient skin permeation rate
Effect can further be reinforced, and depend on the concentration of ATP.
Above only describes better embodiments of the invention, not do any type of limitation to the application, although this
Application discloses as above in a preferred embodiment thereof, however not to limit the application, any person skilled in the art, In
In the range of not departing from technical scheme, it is equivalent that a little variation or modification are made using the technology contents of the disclosure above
In equivalence enforcement case, belong in technical proposal scope.
Sequence table
<110>standing grain U.S. biotechnology (Jiaxing) Co., Ltd is edified
<120>Premeabilisation of cells enhancing peptide, composition and its application
<130> 20190701
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 9
<212> PRT
<213>artificial sequence
<220>
<223> CPEP-9
<400> 1
Cys Ser Ser Ser Ser Ser Lys His Cys
1 5
<210> 2
<211> 10
<212> PRT
<213>artificial sequence
<220>
<223> CPEP-10N
<400> 2
Cys Ser Ser Ser Ser Ser Lys His Cys Gly
1 5 10
<210> 3
<211> 10
<212> PRT
<213>artificial sequence
<220>
<223> CPEP-10C
<400> 3
Ala Cys Ser Ser Ser Ser Ser Lys His Cys
1 5 10
<210> 4
<211> 11
<212> PRT
<213>artificial sequence
<220>
<223> CPEP-11
<400> 4
Ala Cys Ser Ser Ser Ser Ser Lys His Cys Gly
1 5 10
Claims (10)
1. Premeabilisation of cells enhances peptide, there is the amino acid sequence illustrated such as any one of SEQ ID NO.1-4.
2. composition, it includes:
Polypeptide factor, and
Any combination of any one or they in Premeabilisation of cells according to claim 1 enhancing peptide.
3. composition according to claim 2, wherein by weight, the polypeptide factor and Premeabilisation of cells enhancing peptide it
Than for 5~10:1.
4. composition according to claim 2, wherein the composition includes containing there are four types of the groups of Premeabilisation of cells enhancing peptide
It closes, the described enhancing of four kinds of Premeabilisation of cells Peptide C PEP-9, CPEP-10N, CPEP-10C and CPEP-11 are respectively provided with such as SEQ ID
The amino acid sequence that NO.1-4 is illustrated, and by weight, the ratio between each Premeabilisation of cells enhancing peptide CPEP-9:CPEP-10N:
CPEP-10C:CPEP-11 is 0.5~1.5:0.5~1.5:0.5~1.5:1~3.
5. composition according to claim 2, wherein the polypeptide factor selected from the people EGF factor, the people PDGF factor,
Any combination of any one or they in the HGF factor.
6. composition according to claim 2, wherein the composition also includes ATP.
7. composition according to claim 6, wherein the additional amount of the ATP is the weight that the Premeabilisation of cells enhances peptide
1~5 times of amount.
8. the preparation method of composition described in any one of claim 2-7, the method includes seeping polypeptide factor, cell
Enhancing peptide is mixed with optional ATP thoroughly.
9. prepared by composition described in Premeabilisation of cells enhancing any one of peptide and/or claim 2-7 described in claim 1
Application in cosmetics or skin care item.
10. application according to claim 9, wherein the cosmetics or skin care item also include that other cosmetics are acceptable
Component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910585047.1A CN110526957B (en) | 2019-07-01 | 2019-07-01 | Cell permeation enhancing peptides, compositions and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910585047.1A CN110526957B (en) | 2019-07-01 | 2019-07-01 | Cell permeation enhancing peptides, compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110526957A true CN110526957A (en) | 2019-12-03 |
| CN110526957B CN110526957B (en) | 2020-11-13 |
Family
ID=68659548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910585047.1A Active CN110526957B (en) | 2019-07-01 | 2019-07-01 | Cell permeation enhancing peptides, compositions and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110526957B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4023208A1 (en) * | 2020-12-31 | 2022-07-06 | ImDerma Laboratories Co., Ltd. | Topical compositions for skin comprising a cell penetrating peptide and methods of using the same |
| CN114920799A (en) * | 2022-02-19 | 2022-08-19 | 禾美生物科技(浙江)有限公司 | Active peptide with anti-dark eye activity |
| CN115340592A (en) * | 2021-09-09 | 2022-11-15 | 禾美生物科技(浙江)有限公司 | Active peptide and related application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879888A (en) * | 2006-02-15 | 2006-12-20 | 中国科学技术大学 | Transdermal drug administration intensifier and its usage method |
| US20080305989A1 (en) * | 2005-09-15 | 2008-12-11 | Long-Ping Wen | Transdermal delivery peptides and method of use thereof |
| CN102225206A (en) * | 2011-06-17 | 2011-10-26 | 中国科学技术大学 | Composite for enhancing transdermal administration and application thereof |
| CN102247603A (en) * | 2011-06-13 | 2011-11-23 | 中国科学技术大学 | Method for promoting epidermal growth factor transdermal drug delivery of protein drug |
| CN108186392A (en) * | 2018-02-26 | 2018-06-22 | 成都元素平衡生物科技有限公司 | A kind of cosmetology composition containing epithelical cell growth factor and its preparation method and application |
-
2019
- 2019-07-01 CN CN201910585047.1A patent/CN110526957B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080305989A1 (en) * | 2005-09-15 | 2008-12-11 | Long-Ping Wen | Transdermal delivery peptides and method of use thereof |
| CN1879888A (en) * | 2006-02-15 | 2006-12-20 | 中国科学技术大学 | Transdermal drug administration intensifier and its usage method |
| CN102247603A (en) * | 2011-06-13 | 2011-11-23 | 中国科学技术大学 | Method for promoting epidermal growth factor transdermal drug delivery of protein drug |
| CN102225206A (en) * | 2011-06-17 | 2011-10-26 | 中国科学技术大学 | Composite for enhancing transdermal administration and application thereof |
| CN108186392A (en) * | 2018-02-26 | 2018-06-22 | 成都元素平衡生物科技有限公司 | A kind of cosmetology composition containing epithelical cell growth factor and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| YONGPING CHEN等: "Transdermal protein delivery by a coadministered peptide identified via phage display", 《NATURE BIOTECHNOLOGY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4023208A1 (en) * | 2020-12-31 | 2022-07-06 | ImDerma Laboratories Co., Ltd. | Topical compositions for skin comprising a cell penetrating peptide and methods of using the same |
| CN115340592A (en) * | 2021-09-09 | 2022-11-15 | 禾美生物科技(浙江)有限公司 | Active peptide and related application thereof |
| CN114920799A (en) * | 2022-02-19 | 2022-08-19 | 禾美生物科技(浙江)有限公司 | Active peptide with anti-dark eye activity |
| CN114920799B (en) * | 2022-02-19 | 2023-10-24 | 禾美生物科技(浙江)有限公司 | Active peptide with anti-black eye activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110526957B (en) | 2020-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110237022A (en) | A kind of freeze-dried powder, solvent and its application | |
| CN110526957A (en) | Premeabilisation of cells enhances peptide, composition and its application | |
| CN101296939B (en) | Peptides for promoting hair growth and improving wrinkle and cosmetic compositions comprising the same | |
| ES2702388T3 (en) | Peptides derived from the WNT family and uses of these | |
| ES2226960T3 (en) | TURKESTANICA AJUGA EXTRACT AND ITS USES IN COSMETICS. | |
| CN107106617A (en) | Include the cosmetics and/or medical composition and its use of product outside the bacterial cell from South Pole Pseudoalteromonas | |
| CN109350595A (en) | A kind of cosmetics and its preparation method and application containing bird's nest active extract | |
| CN109568169B (en) | Active polypeptide with hair growth effect | |
| CN110072875A (en) | For treat and/or nursing skin, hair, nail and/or mucous membrane compound | |
| KR101933685B1 (en) | Drug Coated Microneedle and Manufacturing Method Thereof | |
| KR20100031862A (en) | Novel palmitoyltripeptide and anti-wrinkle cosmetic composition containing it | |
| CN105878131A (en) | Anti-aging cosmetic composition with plant-cell active substances and polypeptide | |
| CN108714111A (en) | A kind of cell-penetrating peptide-acetyl group Argireline nano-emulsion and preparation method thereof | |
| CN110063911A (en) | A kind of compound small active peptides Essence | |
| CN111888279B (en) | Method for promoting collagen production and corresponding medicine or cosmetic | |
| CN1875920B (en) | Recombinant human serum albumin and yeast ferment mixture, composition containing said mixture, preparation process and use thereof | |
| KR101451340B1 (en) | Composition for hair-growth | |
| CN109966170B (en) | Flexible liposome cosmetic containing biological macromolecules and preparation method thereof | |
| CN103110534B (en) | Combined essence of composite velvet antler polypeptide lyophilized powder and nano-scale buffering microemulsion for skin beauty and health care and preparation method of combined essence | |
| CN107334739A (en) | A kind of fibroblast growth factor liposome freeze-dried powder for preventing and treating alopecia and preparation method thereof | |
| CN111961119A (en) | Application of polypeptide in preparation of medicine or cosmetic for promoting collagen secretion | |
| CN115068352B (en) | Oil control polypeptide flexible liposome hydrogel and preparation method and application thereof | |
| Dawson et al. | Transdermal delivery of a melanotropic peptide hormone analogue | |
| CN108785136B (en) | Application of cedar essential oil | |
| CN109730943A (en) | A kind of anti-wrinkle composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 314000 room 14f1401-b, No. 705, Asia Pacific Road, Nanhu District, Jiaxing City, Zhejiang Province Patentee after: Hemei Biotechnology (Zhejiang) Co.,Ltd. Address before: 314000 room 14f1401-b, No. 705, Asia Pacific Road, Nanhu District, Jiaxing City, Zhejiang Province Patentee before: Enlightenment Hemei Biotechnology (Jiaxing) Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |